AGN up +0.60% percent Today $AGN High is at 198.00
Post# of 338555
Posted On: 11/13/2014 12:13:32 PM
AGN up +0.60% percent Today $AGN High is at 198.00 and the Low 196.61 with current volume of 248,780.
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 196.60 (+0.09), VRX: 132.28 (+1.19), ACT: 242.24 (+1.62)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.60 (+0.09), JNJ: 108.93 (+0.18), GILD: 104.30 (-2.60), ABBV: 63.98 (+0.22)
FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 196.60 (+0.09)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 42.95 (+0.31), AGN: 196.60 (+0.09), VRX: 132.28 (+1.19), ACT: 242.24 (+1.62)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 196.60 (+0.09), ACT: 242.24 (+1.62)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.60 (+0.09), ABBV: 63.97 (+0.21), SNY: 46.62 (+0.06), REGN: 398.61 (-2.50)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 42.95 (+0.31), AGN: 196.60 (+0.09), HLF: 37.74 (-0.07), VRX: 132.28 (+1.19), PFE: 30.48 (+0.06), MRK: 59.73 (+0.42), LLY: 67.87 (+0.47)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.84 (-0.05), AGN: 196.60 (+0.09), ACT: 242.24 (+1.62), IRWD: 13.38 (-0.37), CBST: 72.57 (+0.26), PFE: 30.48 (+0.06)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 196.60 (+0.09), VRX: 132.28 (+1.19)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.70 (-0.11), SJR: 26.20 (unch), PRGO: 155.33 (+0.46), XYL: 37.44 (-0.11), CHRW: 72.88 (+0.02), MDLZ: 38.07 (+0.15), MKC: 73.45 (+0.22), MDU: 25.20 (-0.22), SYY: 38.79 (-0.15), PDCO: 45.60 (+0.47), PNR: 68.21 (-0.23), TRI: 38.09 (-0.15), UPS: 108.12 (-0.50), PEP: 98.47 (+1.31), AGN: 196.59 (+0.08), MSI: 64.30 (+0.60), NOV: 70.97 (-2.03), NWN: 47.07 (-0.02), EGN: 66.65 (-2.05), EBAY: 54.35 (+0.29), QCOM: 70.57 (+0.28), AMAT: 22.70 (+0.21), ACN: 84.30 (+0.18), AAPL: 113.19 (+1.94), MA: 84.06 (-0.29), SCHW: 28.70 (-0.08), STR: 23.92 (-0.02), SE: 38.14 (-0.82), GAS: 51.93 (-0.19), IRM: 38.05 (unch), WM: 49.37 (-0.01), CMP: 88.85 (+0.16), VRSK: 62.77 (-0.35), GILD: 104.30 (-2.60), EXPD: 43.84 (-0.07), TFX: 114.53 (+0.06), CVS: 89.89 (+0.60), PG: 89.30 (-0.18), PX: 126.19 (-0.04), NVS: 94.48 (+1.82)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 196.59 (+0.08)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.59 (+0.08), GILD: 104.30 (-2.60), ABBV: 63.96 (+0.20), BMY: 57.82 (-0.79)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 196.59 (+0.08), VRX: 132.20 (+1.11), ACT: 242.24 (+1.62)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.60 (+0.27), AGN: 196.59 (+0.08), JNJ: 108.94 (+0.19), DNDN: 0.14 (-0.02)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 196.59 (+0.08), ZTS: 42.95 (+0.31), ACT: 242.24 (+1.62), VRX: 132.20 (+1.11)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.84 (-0.05), AGN: 196.59 (+0.08), ACT: 242.24 (+1.62), VRX: 132.20 (+1.11), MDT: 69.39 (+0.89), SLXP: 95.92 (+0.37), SNY: 46.62 (+0.06)
New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA)
PR Newswire - Tue Nov 11, 7:47AM CST
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks(TM), an online community of women, reveals what they really want to know about it.1 To address the most common questions women have - and there are nearly 10 million women who are considering treatment2 - Allergan, Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
AGN: 196.59 (+0.08)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 196.58 (+0.07), GILD: 104.31 (-2.59), MRK: 59.71 (+0.40), ABBV: 63.96 (+0.20)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 196.58 (+0.07), VRX: 132.20 (+1.11), AUXL: 32.50 (-0.02), SLXP: 95.92 (+0.37)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 196.58 (+0.07), EBS: 24.53 (-0.39), ABAX: 55.09 (+0.89), ABBV: 63.96 (+0.20)
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Allergan buyout said nearing
at Investor's Business Daily - Wed Nov 12, 5:51PM CST
Drugmaker Actavis (ACT) is reportedly near a deal to take over Botox maker Allergan (AGN) for at least $60 bil. An agreement could be reached in a matter of weeks, said Bloomberg sources. But in order to avoid a looming hostile takeover bid from...
AGN: 196.60 (+0.09), VRX: 132.28 (+1.19), ACT: 242.24 (+1.62)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.60 (+0.09), JNJ: 108.93 (+0.18), GILD: 104.30 (-2.60), ABBV: 63.98 (+0.22)
FDA Approves New Styles of Allergan's NATRELLE(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
Business Wire - Wed Nov 12, 3:50PM CST
Allergan, Inc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.
AGN: 196.60 (+0.09)
Actavis, Allergan Reported Near Deal As Valeant Lurks
at Investor's Business Daily - Wed Nov 12, 11:43AM CST
The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been...
ZTS: 42.95 (+0.31), AGN: 196.60 (+0.09), VRX: 132.28 (+1.19), ACT: 242.24 (+1.62)
Actavis closing in on Allergan
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:22AM CST
AGN: 196.60 (+0.09), ACT: 242.24 (+1.62)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.60 (+0.09), ABBV: 63.97 (+0.21), SNY: 46.62 (+0.06), REGN: 398.61 (-2.50)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 42.95 (+0.31), AGN: 196.60 (+0.09), HLF: 37.74 (-0.07), VRX: 132.28 (+1.19), PFE: 30.48 (+0.06), MRK: 59.73 (+0.42), LLY: 67.87 (+0.47)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.84 (-0.05), AGN: 196.60 (+0.09), ACT: 242.24 (+1.62), IRWD: 13.38 (-0.37), CBST: 72.57 (+0.26), PFE: 30.48 (+0.06)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 196.60 (+0.09), VRX: 132.28 (+1.19)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.70 (-0.11), SJR: 26.20 (unch), PRGO: 155.33 (+0.46), XYL: 37.44 (-0.11), CHRW: 72.88 (+0.02), MDLZ: 38.07 (+0.15), MKC: 73.45 (+0.22), MDU: 25.20 (-0.22), SYY: 38.79 (-0.15), PDCO: 45.60 (+0.47), PNR: 68.21 (-0.23), TRI: 38.09 (-0.15), UPS: 108.12 (-0.50), PEP: 98.47 (+1.31), AGN: 196.59 (+0.08), MSI: 64.30 (+0.60), NOV: 70.97 (-2.03), NWN: 47.07 (-0.02), EGN: 66.65 (-2.05), EBAY: 54.35 (+0.29), QCOM: 70.57 (+0.28), AMAT: 22.70 (+0.21), ACN: 84.30 (+0.18), AAPL: 113.19 (+1.94), MA: 84.06 (-0.29), SCHW: 28.70 (-0.08), STR: 23.92 (-0.02), SE: 38.14 (-0.82), GAS: 51.93 (-0.19), IRM: 38.05 (unch), WM: 49.37 (-0.01), CMP: 88.85 (+0.16), VRSK: 62.77 (-0.35), GILD: 104.30 (-2.60), EXPD: 43.84 (-0.07), TFX: 114.53 (+0.06), CVS: 89.89 (+0.60), PG: 89.30 (-0.18), PX: 126.19 (-0.04), NVS: 94.48 (+1.82)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 196.59 (+0.08)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.59 (+0.08), GILD: 104.30 (-2.60), ABBV: 63.96 (+0.20), BMY: 57.82 (-0.79)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 196.59 (+0.08), VRX: 132.20 (+1.11), ACT: 242.24 (+1.62)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 106.60 (+0.27), AGN: 196.59 (+0.08), JNJ: 108.94 (+0.19), DNDN: 0.14 (-0.02)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 196.59 (+0.08), ZTS: 42.95 (+0.31), ACT: 242.24 (+1.62), VRX: 132.20 (+1.11)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.84 (-0.05), AGN: 196.59 (+0.08), ACT: 242.24 (+1.62), VRX: 132.20 (+1.11), MDT: 69.39 (+0.89), SLXP: 95.92 (+0.37), SNY: 46.62 (+0.06)
New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA)
PR Newswire - Tue Nov 11, 7:47AM CST
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks(TM), an online community of women, reveals what they really want to know about it.1 To address the most common questions women have - and there are nearly 10 million women who are considering treatment2 - Allergan, Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
AGN: 196.59 (+0.08)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 196.58 (+0.07), GILD: 104.31 (-2.59), MRK: 59.71 (+0.40), ABBV: 63.96 (+0.20)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 196.58 (+0.07), VRX: 132.20 (+1.11), AUXL: 32.50 (-0.02), SLXP: 95.92 (+0.37)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 196.58 (+0.07), EBS: 24.53 (-0.39), ABAX: 55.09 (+0.89), ABBV: 63.96 (+0.20)
(0)
(0)